Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | NTRK gene fusions in sarcoma

Robin Jones • 20 Apr 2022
Sarcoma

Significant response rates to NTRK inhibitors have been demonstrated in patients with sarcoma harboring NTRK gene fusions in regards to progression-free survival (PFS) and overall-survival (OS). Robin Jones, MD, The Royal Marsden Hospital, London, UK, mentions specific data whereby a median PFS of 28.3 months and an OS of 44.4 months was observed with a favorable toxicity profile, highlighting the value of identifying NTRK gene fusions in patients with sarcoma.

More from Robin Jones

0:58
Challenges in advanced GIST: tackling resistance to therapies
Robin Jones • 4 Jun 2023
0:36
Current treatment landscape for patients with advanced gastrointestinal stromal tumor (GIST)
Robin Jones • 3 Jun 2023
1:13
Updated overall survival findings from the Phase III INTRIGUE trial
Robin Jones • 4 Jun 2023
0:34
INTRIGUE: ripretinib versus sunitinib in GIST
Robin Jones • 4 Jun 2023

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadezhda Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadezhda Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals